Singular Immune
Singular’s iCAR is a recombinant fusion-protein approach to modifying T or NK cells in vivo. It is kept separate from gene-encoded CAR-T because protein-based receptor installation has a different mechanism. The website does not establish human efficacy.
Corporate information
- Company entity
- Singular Immune
- Headquarters / principal office
- No verified public location identified
- Founded
- Not verified
- Ownership / capital status
- Not verifiedNot verified
- Official corporate reference
- https://singularimmune.com/ ↗
- LinkedIn company page
- Independent company page not verified
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Start with public sources and capability boundaries; company claims are not independent certification.
Ask AI ↗Public evidence snapshot
Singular’s iCAR is a recombinant fusion-protein approach to modifying T or NK cells in vivo. It is kept separate from gene-encoded CAR-T because protein-based receptor installation has a different mechanism. The website does not establish human efficacy.
This profile is a research snapshot, not a company endorsement. Check original sources for current information.